A lipidated anti-Tat antibody enters living cells and blocks HIV-1 viral replication
Biochemistry & Molecular Pharmacology
Graduate School of Biomedical Sciences; Department of Medicine, Division of Pulmonary, Allergy & Critical Care
Life Sciences | Medicine and Health Sciences
We have developed a chemical modification of antibodies, lipidation, which enables their intracellular delivery into living cells. Intracellular localization of lipidated antibodies was demonstrated by confocal microscopy and by measuring cellular uptake of 125I-labeled lipidated antibodies. Functionally, a lipidated monoclonal antibody directed against the Tat protein from human immunodeficiency virus type 1 (HIV-1) inhibited viral replication of several HIV-1 isolates by approximately 85% as shown by increased viability of infected cells and decreased reverse transcriptase activity. The antibody in its native form had no such effect. These data show that lipidated antibodies can reach and functionally inhibit intracellular targets. Lipidation may help to facilitate the development of intracellular immunotherapy for AIDS.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):193-203.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
Cruikshank WW, Doctrow SR, Falvo MS, Huffman K, Maciaszek JW, Viglianti GA, Raina J, Kornfeld H, Malfroy B. (1997). A lipidated anti-Tat antibody enters living cells and blocks HIV-1 viral replication. GSBS Student Publications. Retrieved from https://escholarship.umassmed.edu/gsbs_sp/256